Sickle Cell Disease Treatment Demonstration Program, 44575 [2013-17720]
Download as PDF
<![CDATA[
44575
Federal Register / Vol. 78, No. 142 / Wednesday, July 24, 2013 / Notices
Dated: July 19, 2013.
Leslie Kux,
Assistant Commissioner for Policy.
[FR Doc. 2013–17769 Filed 7–23–13; 8:45 am]
BILLING CODE 4160–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Health Resources and Services
Administration
Sickle Cell Disease Treatment
Demonstration Program
Health Resources and Services
Administration (HRSA), Department of
Health and Human Services (HHS).
ACTION: Request for Class Deviation for
Non-Competitive Extension: Sickle Cell
Disease Treatment Demonstration
Program (U1E) Awards to Three
Currently Funded Grantees.
AGENCY:
HRSA currently has nine
programs that are funded through
competitive grant awards under the
Sickle Cell Disease Treatment
Demonstration Program. Three of these
SUMMARY:
awards will end on August 31, 2013,
prior to the end of the other six awards.
HRSA intends to implement a noncompetitive extension of the project
period for the three grants that will end
in 2013. This will allow improved data
gathering from each of the grantees in
the program, which will be used in a
report for Congress that is mandated by
the legislation authorizing the grant. In
addition, the program will benefit from
cost savings realized from having the
program completed in a consolidated
funding cycle.
SUPPLEMENTARY INFORMATION:
Intended Recipients of the Award:
The three incumbent grantees of record
(listed below).
Amount of the Non-Competitive
Awards: Up to $390,000 per grantee.
CFDA Number: 93.365.
Period of Supplemental Funding: 9/1/
2013–8/30/2014.
Authority: Section 712(c) of the American
Jobs Creation Act of 2004, Pub. L. 108–357.
Justification: The Sickle Cell Disease
Treatment Demonstration Program
provides grants to evaluate the use of
strategies in improving sickle cell care.
The extension will allow the Maternal
and Child Health Bureau to fully assess
the impact of the program by allowing
data to be gathered on the health
outcomes and impact of the Sickle Cell
Disease Treatment Demonstration
Program from all grantees on the same
timeline and in a standard format.
Currently, three grantees are scheduled
to end prior to the end of the other
grantees, leaving a period in which data
would not be gathered from these sites.
Data gathered from each of the grantees
in the program will be used in a report
for Congress that is mandated by the
legislation authorizing the grant. In
addition, the program will benefit from
cost savings realized from having the
program completed in a consolidated
funding cycle.
FOR FURTHER INFORMATION CONTACT:
Edward Donnell Ivy, M.D., M.P.H,
Genetic Services Branch, Division of
Services for Children with Special
Health Needs, Maternal and Child
Health Bureau, Health Resources and
Services Administration, 5600 Fishers
Lane, Room 18A–19, Rockville, MD
20857; 301.443.9775; eivy@hrsa.gov.
MATERNAL AND CHILD HEALTH BUREAU SELECTED PROGRAMS EXTENSIONS WITH FUNDING
Project end
date
Revised
project end
date
FY 2012
Appropriation
FY 2013
Appropriation
Grant No.
Children’s Hospital & Research
Center.
University of Colorado at Denver.
Newark Beth Israel Medical
Center.
U1EMC16492
CA
9/1/2009
8/31/2013
8/30/2014
$390,000
$390,000
U1EMC16490
CO
9/1/2009
8/31/2013
8/30/2014
390,000
390,000
U1EMC16491
NJ
9/1/2009
8/31/2013
8/30/2014
390,000
390,000
Dated: July 17, 2013.
Mary K. Wakefield,
Administrator.
[FR Doc. 2013–17720 Filed 7–23–13; 8:45 am]
BILLING CODE 4165–15–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
sroberts on DSK5SPTVN1PROD with NOTICES
Office of the Director, National
Institutes of Health; Notice of Meeting
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. Appendix 2), notice
is hereby given of the meeting of the
Council of Councils.
The meeting will be held via
teleconference and is open to the public
as indicated below. Individuals who
need special assistance, such as sign
language interpretation or other
VerDate Mar<15>2010
16:35 Jul 23, 2013
Jkt 229001
State
Project start
date
Grantee/organization name
reasonable accommodations, should
notify the Contact Person listed below
in advance of the meeting.
A portion of the meeting will be
closed to the public in accordance with
the provisions set forth in sections
552b(c)(4), and 552b(c)(6), Title 5
U.S.C., as amended. The grant
applications and the discussions could
disclose confidential trade secrets or
commercial property such as patentable
material, and personal information
concerning individuals associated with
the grant applications, the disclosure of
which would constitute a clearly
unwarranted invasion of personal
privacy.
Name of Committee: Council of Councils.
Open: August 15, 2013, 1:00 p.m. to 1:40
p.m.
Agenda: Establishment of Chimpanzee
Research Use Panel and Discussion. Vote on
Establishment of the Panel. NIH Director’s
Early Independence Awards.
PO 00000
Frm 00057
Fmt 4703
Sfmt 4703
Place: National Institutes of Health,
Building 1, Room 260, 1 Center Drive,
Bethesda, MD 20892.
Dial in number: 1–888–790–1964.
Participant Passcode: 9121608.
Closed: August 15, 2013, 1:45 p.m. to 2:15
p.m.
Agenda: Review of Grant Applications.
Contact Person: Robin Kawazoe, Executive
Secretary, Division of Program Coordination,
Planning, and Strategic Initiatives, Office of
the Director, NIH, Building 1, Room 260,
Bethesda, MD 20892,
kawazoer@mail.nih.gov.
Any interested person may file written
comments with the committee by forwarding
the statement to the Contact Person listed on
this notice. The statement should include the
name, address, telephone number and when
applicable, the business or professional
affiliation of the interested person.
Information is also available on the Council
of Council’s home page at https://
dpcpsi.nih.gov/council/where an agenda and
proposals to be discussed will be posted
before the meeting date.
E:\FR\FM\24JYN1.SGM
24JYN1
]]>Agencies
[Federal Register Volume 78, Number 142 (Wednesday, July 24, 2013)]
[Notices]
[Page 44575]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2013-17720]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Health Resources and Services Administration
Sickle Cell Disease Treatment Demonstration Program
AGENCY: Health Resources and Services Administration (HRSA), Department
of Health and Human Services (HHS).
ACTION: Request for Class Deviation for Non-Competitive Extension:
Sickle Cell Disease Treatment Demonstration Program (U1E) Awards to
Three Currently Funded Grantees.
-----------------------------------------------------------------------
SUMMARY: HRSA currently has nine programs that are funded through
competitive grant awards under the Sickle Cell Disease Treatment
Demonstration Program. Three of these awards will end on August 31,
2013, prior to the end of the other six awards. HRSA intends to
implement a non-competitive extension of the project period for the
three grants that will end in 2013. This will allow improved data
gathering from each of the grantees in the program, which will be used
in a report for Congress that is mandated by the legislation
authorizing the grant. In addition, the program will benefit from cost
savings realized from having the program completed in a consolidated
funding cycle.
SUPPLEMENTARY INFORMATION:
Intended Recipients of the Award: The three incumbent grantees of
record (listed below).
Amount of the Non-Competitive Awards: Up to $390,000 per grantee.
CFDA Number: 93.365.
Period of Supplemental Funding: 9/1/2013-8/30/2014.
Authority: Section 712(c) of the American Jobs Creation Act of
2004, Pub. L. 108-357.
Justification: The Sickle Cell Disease Treatment Demonstration
Program provides grants to evaluate the use of strategies in improving
sickle cell care. The extension will allow the Maternal and Child
Health Bureau to fully assess the impact of the program by allowing
data to be gathered on the health outcomes and impact of the Sickle
Cell Disease Treatment Demonstration Program from all grantees on the
same timeline and in a standard format. Currently, three grantees are
scheduled to end prior to the end of the other grantees, leaving a
period in which data would not be gathered from these sites. Data
gathered from each of the grantees in the program will be used in a
report for Congress that is mandated by the legislation authorizing the
grant. In addition, the program will benefit from cost savings realized
from having the program completed in a consolidated funding cycle.
FOR FURTHER INFORMATION CONTACT: Edward Donnell Ivy, M.D., M.P.H,
Genetic Services Branch, Division of Services for Children with Special
Health Needs, Maternal and Child Health Bureau, Health Resources and
Services Administration, 5600 Fishers Lane, Room 18A-19, Rockville, MD
20857; 301.443.9775; eivy@hrsa.gov.
Maternal and Child Health Bureau Selected Programs Extensions With Funding
--------------------------------------------------------------------------------------------------------------------------------------------------------
Revised
Grantee/organization name Grant No. State Project start Project end project end FY 2012 FY 2013
date date date Appropriation Appropriation
--------------------------------------------------------------------------------------------------------------------------------------------------------
Children's Hospital & Research Center U1EMC16492 CA 9/1/2009 8/31/2013 8/30/2014 $390,000 $390,000
University of Colorado at Denver..... U1EMC16490 CO 9/1/2009 8/31/2013 8/30/2014 390,000 390,000
Newark Beth Israel Medical Center.... U1EMC16491 NJ 9/1/2009 8/31/2013 8/30/2014 390,000 390,000
--------------------------------------------------------------------------------------------------------------------------------------------------------
Dated: July 17, 2013.
Mary K. Wakefield,
Administrator.
[FR Doc. 2013-17720 Filed 7-23-13; 8:45 am]
BILLING CODE 4165-15-P
